ArticleBioImpacts : BI2012
Impacts of blood-brain barrier in drug delivery and targeting of brain tumors.
Article in BioImpacts : BI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Impact of EGFR mutation subtypes and TKI generations on clinical outcomes in lung adenocarcinoma patients with brain metastases treated with gamma knife radiosurgery.Journal of neuro-oncology · 2025Article
- Article
- Overcoming challenges in the design of drug delivery systems targeting the central nervous system.Nanomedicine (London, England) · 2025Article
- GDNF and cAMP significantly enhanceHeliyon · 2024Article
- Drug delivery for neurodegenerative diseases is a problem, but lipid nanocarriers could provide the answer.Nanotheranostics · 2024Review
- Nature vs. Manmade: Comparing Exosomes and Liposomes for Traumatic Brain Injury.The AAPS journal · 2023Review
- Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?Current neuropharmacology · 2022Review
- Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration.Antibodies (Basel, Switzerland) · 2021Review
- Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems.Current neuropharmacology · 2021Article
- The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review.Cancers · 2020Review
- Therapeutic impacts of enzyme-responsive smart nanobiosystems.BioImpacts : BI · 2020Article
- Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model.Scientific reports · 2019Article
- Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis.Cellular and molecular life sciences : CMLS · 2019Review
- Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates.BioImpacts : BI · 2019Article
- Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport.Chemical science · 2018Article
- Cancer immunotherapy in patients with brain metastases.Cancer immunology, immunotherapy : CII · 2018Review
- An In Vivo Assessment of Blood-Brain Barrier Disruption in a Rat Model of Ischemic Stroke.Journal of visualized experiments : JoVE · 2018Article
- Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective.BioImpacts : BI · 2018Review
- Review
- Pericytes, an overlooked player in vascular pathobiology.Pharmacology & therapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEntry of blood circulating agents into the brain is highly selectively con-trolled by specific transport machineries at the blood brain barrier (BBB), whose excellent barrier restrictiveness make brain drug delivery and targeting very challenging.
methodsEssential information on BBB cellular microenvironment were reviewed and discussed towards impacts of BBB on brain drug delivery and targeting.
resultsBrain capillary endothelial cells (BCECs) form unique biological structure and architecture in association with astrocytes and pericytes, in which microenvironment the BCECs express restrictive tight junctional complexes that block the paracellular inward/outward traverse of biomolecules/compounds. These cells selectively/specifically control the transportation process through carrier and/or receptor mediated transport machineries that can also be exploited for the delivery of pharmaceuticals into the brain. Intelligent molecular therapies should be designed using such transport machineries for the efficient delivery of designated drugs into the brain. For better clinical outcomes, these smart pharmaceuticals should be engineered as seamless nanosystems to provide simultaneous imaging and therapy (multimodal theranostics).
conclusionThe exceptional functional presence of BBB selectively controls inward and outward transportation mechanisms, thus advanced smart multifunctional nanomedicines are needed for the effective brain drug delivery and targeting. Fully understanding the biofunctions of BBB appears to be a central step for engineering of intelligent seamless therapeutics consisting of homing device for targeting, imaging moiety for detecting, and stimuli responsive device for on-demand liberation of therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.